Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Michela Facchin"'
Autor:
Monica De Gaspari, Stefania Rizzo, Mauro Cassaro, Michela Facchin, Roberto Verlato, Cristina Basso, Paolo Buja
Publikováno v:
European Heart Journal Supplements. 24
Background Coronary ostial lesions are a rare entity and isolated coronary ostial stenosis is even less frequent. Diffuse coronary artery atherosclerosis is the main cause for the non-isolated stenosis, based on old post-mortem series and histologica
Autor:
Henrique Barbosa Ribeiro, Kanhaiya L. Poddar, Giuseppe Tarantini, Rahul Sharma, James Mirocha, Jean Fajadet, Luca Testa, Samir R. Kapadia, Jigar Patel, Horst Sievert, Michela Facchin, Antonio Colombo, Thierry Lefèvre, Wen Cheng, George Matar, Murat Tuzcu, Tarun Chakravarty, Josep Rodés-Cabau, Brian R. Lindman, Gennaro Giustino, Nobuyuki Takahashi, Hasan Jilaihawi, Ariel Finkelstein, Raj Makkar, Yigal Abramowitz, Didier Tchetche, Babak Hariri, Benoit Monteil, Azeem Latib
Publikováno v:
Journal of the American College of Cardiology. 67:951-960
Background A percutaneous approach with transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI) of the left main coronary artery (LM) is frequently used in high-risk patients with coexisting aortic stenosis and LM d
Autor:
Paolo Buja, Augusto D'Onofrio, Roberto Bianco, Massimo Napodano, Chiara Fraccaro, Sabino Iliceto, Ermela Yzeiraj, Laura Besola, Michela Facchin, Eleonora Bizzotto, Elisa Covolo, Demetrio Pittarello, Chiara Tessari, Gino Gerosa, Giuseppe Tarantini, Giambattista Isabella, Erica Manzan
Publikováno v:
The Annals of Thoracic Surgery. 101:881-888
Concerns still exist regarding long-term results and freedom from valve-related adverse events in transcatheter aortic valve implantation (TAVI). The aim of this single-center retrospective study was to assess intermediate-term (up to 5-year) clinica
Autor:
Gabriele Gabrielli, Massimo Fineschi, Donatella Corrado, Leonardo Misuraca, Maurizio Ferrario, Bruno Loi, Elisabetta Moscarella, Sebastian Coscarelli, Maria Carmen De Angelis, Gabriele Tumminello, Francesco Pisano, Paolo Calabrò, Bernardo Cortese, Alfonso Ielasi, Michela Facchin, Attilio Varricchio, Roberto Gistri, Maurizio Tespili, Pietro Mazzarotto, Alessandro Colombo, Giuseppe Tarantini, Davide Piraino, Alessandro Durante, Valerio Lucci, Giuseppe Steffenino, Luciano Moretti, Annamaria Nicolino
Background The bioresorbable vascular scaffold (BVS) technology may be an appealing option in ST-segment elevation myocardial infarction (STEMI) patients. However, the available evidence on its use in this challenging subset is limited. Methods Regis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b29fe0e77ac677b4216546b69e39f51
http://hdl.handle.net/11577/3279421
http://hdl.handle.net/11577/3279421
Autor:
Giambattista Isabella, Corrado Tamburino, Davide Capodanno, Michela Facchin, Alberto Menozzi, Giuseppe Tarantini, Corrado Lettieri, Paolo Buja, Massimo Napodano, Anna Chiara Frigo, Michael S. Lee, Gennaro Sardella, Francesco Saia, Mauro De Benedictis, Alberto Barioli, Giuseppe Musumeci, Gianpiero D'Amico
Publikováno v:
International Journal of Cardiology. 168:139-143
Background Gender-based differences in diabetic patients are understudied in the field of percutaneous coronary intervention (PCI) with drug-eluting stents. Methods Data were obtained from a multicenter registry of 2420 consecutive patients with diab
Autor:
Massimo Napodano, Anna C. Frigo, Giuseppe Tarantini, Alberto Barioli, Sabino Iliceto, Giambattista Isabella, Paolo Buja, Michela Facchin, Gianpiero D'Amico
Publikováno v:
Coronary Artery Disease. 24:440-448
OBJECTIVE: Drug-eluting stents are more effective in reducing restenosis than bare-metal stents. Paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES) are the most widely used first-generation drug-eluting stents, but long-term comparati
Autor:
Massimo Napodano, Anna Chiara Frigo, Sabino Iliceto, Paola Purita, Michela Facchin, Augusto D'Onofrio, Elisa Covolo, Giuseppe Tarantini, Marco Mojoli, Giambattista Isabella, Gino Gerosa
AIMS Early data on the Edwards SAPIEN 3 valve (S3-THV) have shown low rates of paravalvular leaks and vascular complications but relatively high 30-day permanent pacemaker implantation (PPMI) rates. No direct comparisons on clinical outcomes includin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ded5858a4af7a8cf6233a532cb6b393
http://hdl.handle.net/11577/3209519
http://hdl.handle.net/11577/3209519
Autor:
Giuseppe Tarantini, Francesco Pisano, Gianfranco Defilippi, Diego Calzolari, Attilio Varricchio, Maurizio D'Urbano, Bernardo Cortese, Valerio Lucci, Alessandro Colombo, Annamaria Nicolino, Michela Facchin, Donatella Corrado, Ugo Limbruno, Maurizio Tespili, Bruno Loi, Dario Buccheri, Luigi LaVecchia, Roberto Gistri, Gianni Tognoni, Gabriele Tumminello, Giuseppe Steffenino, Alfonso Ielasi
Background The Absorb™ BVS is a bioresorbable, everolimus-eluting scaffold approved and marketed for coronary use. Published data on long-term results after treatment are limited to a small number of patients, most of them with elective PCI of simp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e225a93d4d00b8881d5882820f2ddfe
http://hdl.handle.net/11577/3196826
http://hdl.handle.net/11577/3196826
Autor:
Maria Carmen De Angelis, Paolo Calabrò, Bruno Loi, Elisabetta Moscarella, Donatella Corrado, Alessandro Colombo, Michela Facchin, Giuseppe Steffenino, Giuseppe Tarantini, Alfonso Ielasi, Francesco Pisano, Luciano Moretti, Gabriele Tumminello, Attilio Varricchio, Alessandro Durante, Bernardo Cortese
Publikováno v:
Journal of the American College of Cardiology. 69:S1
Bioresorbable vascular scaffold (BVS) technology represents a revolutionary concept in interventional cardiology. It appears an attractive alternative to metallic drug-eluting stents and its use is rapidly extending even to complex lesions. However c
Autor:
Alessandro Sticchi, Antonio Colombo, Cinzia Marrozzini, Toru Naganuma, Massimo Napodano, Antonio Marzocchi, Ottavio Alfieri, Michela Facchin, Azeem Latib, Cristina Ciuca, Brunilda Hoxha, Carolina Moretti, Francesco Saia, Valeria Gasparetto, Giuseppe Tarantini, Laura Anderlucci
Background Transcatheter aortic valve replacement (TAVR) is an effective therapeutic option for patients with severe aortic stenosis at high risk for surgery. Identification of causes of death after TAVR may help improve patient selection and outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7559d7ad8c94bfa13f27b2e2cb35a2b5
http://hdl.handle.net/11577/3156127
http://hdl.handle.net/11577/3156127